Avoiding aggregation during preclinical and clinical phases: our technology allows selection of potential Lead candidates that will not be affected by protein aggregation. Aggregation of peptides, proteins and antibodies during clinical trials phases is a major cause of failure during drug development.
hit-to-lead-team@peaccel.com
Increase the chance of success of Drug lead candidate
